EU GMP Chapter 1 - Pharmaceutical Quality System

What it says

Manufacturers must establish, document and maintain a pharmaceutical quality system incorporating GMP and quality risk management, with senior management holding ultimate responsibility to ensure an effective quality system is in place, adequately resourced, and subject to periodic management review.

Paraphrased for plain-language clarity. Always verify against the current published regulation text.

What it means in practice

• Chapter 1 is the EU equivalent anchor to ICH Q10, explicitly placing ultimate quality system responsibility on senior management rather than treating it as solely the quality unit's domain.
• Management review is a defined, expected activity under this chapter specifically, not simply a general good practice - senior management is expected to actively engage with quality system performance data.
• Adequate resourcing of the quality system is named explicitly as a senior management responsibility, meaning under-resourcing the quality function can itself become a citable gap against this chapter.

What inspectors look for

• Whether senior management can demonstrate genuine engagement with quality system performance, through interview and management review records, not just delegated oversight.
• Whether the quality system is adequately resourced relative to the scale and complexity of the site's operations.
• Whether quality risk management principles are visibly integrated into real operational and business decisions, not confined to formal risk assessment documents.

Related regulations